Research Information System
48th ESCP Symposium. The Digital Revolution: Supporting clinical pharmacy through e-health, digital support systems, big data and more., Ljubljana, Slovenia, 23 - 25 October 2019, pp.229
Background
and Objective: Cancer
treatment is one the most compelling situation for healthcare providers. The
situation itself already complicated enough. In addition, cancer treatment
requires multiple medication usage simultaneously. Drug-drug interactions (DDI)
compose 20-30% of adverse effects. Drug-drug interactions are responsible 4% of
mortality in oncology. Cancer patients are more prone to experience drug-drug
interactions, because of taking multiple medications with anticancer agents to
reduce or prevent the side effects that are caused by chemotherapeutic agents.
Since
the clinical pharmacists have a key role to prevent DDIs and to enhance the
patients’ quality of life, a multidisciplinary approach is an important
necessity in cancer care.
Setting
and Method:
Cross-sectional
observational study was conducted through interviews with 133 patients. In our study we would
like to evaluate DDIs of patient who applied Oncology clinic of Bezmialem Vakif
University Istanbul Turkey. This study has been approved by noninvasive
Clinical Research Ethics Committee of Bezmialem Vakif University with decision
number of 21/286 on 21.112017. Drug-drug
interactions were evaluated using three sources: Lexicomp®, Medscape® and
Micromedex®. Interaction levels have been
taking into consideration were serious-use alternative and monitor closely for Medscape®, Serious-Use
Alternative and Major Micromedex® and
Category X and D for Lexicomp®.
Main
outcome measures: Evaluation
of DDIs in perspective of number and comparison between different clinical
decision support systems.
Results: 244 different medicine prescribed
1712 times to 133 patients. According to our results number of DDIs were
265-1472 (1,99-11,07 DDI/patient) for Medscape®, 38-1006 (0,29-7,56 DDI/patient) for Micromedex and for Lexicomp® were 86-532 (1,99-4,00
DDI/patient).
Conclusion: This study revealed that DDIs is common problem among oncology patients in hospital settings. When pharmacist making a decision using various software and decision support systems with different level of evidences. This study showed us that trusting one software completely could lead clinician to failure. On the other hand, patients with comorbidities, renal impairment and polypharmacy are more prone to have more DRPs.